Delix Therapeutics
Mike Bower is an accomplished computational chemist with extensive experience in drug discovery and development spanning over two decades. Currently serving as Associate Director at Delix Therapeutics, Mike Bower focuses on data analysis and cheminformatics for novel neuroplastogens. Prior to this role, Mike Bower was Principal Computational Chemist at Reverie Labs, leading oncology discovery projects and a computational chemistry team. Previous positions include Senior Research Scientist at Vertex Pharmaceuticals, where Mike Bower specialized in virtual screening, and Associate Director at Incyte Corporation, where Mike Bower established a computational research group. Additionally, Mike Bower has academic experience as an adjunct professor at both Delaware State University and the University of Delaware. Educational credentials include a PhD in Pharmaceutical Chemistry from the University of California, San Francisco, and a Bachelor of Science in Chemistry from the University of Delaware.
This person is not in any teams
Delix Therapeutics
Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.